Clinical Trial Update: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating autologous T cells engineered to express T-cell receptors against neoantigens in metastatic cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endocrine Tumors
• Gastrointestinal Genitourinary Cancers
• Multiple Myeloma
• Neuroendocrine Tumors
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• Autologous T cells expressing neoantigen-reactive T-cell receptors

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endocrine Tumors, Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING